Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of SWOG 9346 (INT-0162), an international phase III trial

Reporter: Gita Suneja, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de junio del 2012

Translation for this article does not exist

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016